Stephen G. Dilly
2018 - Aimmune Therapeutics
In 2018, Stephen G. Dilly earned a total compensation of $2M as Former Chief Executive Officer at Aimmune Therapeutics, a 71% decrease compared to previous year.
Compensation breakdown
| Option Awards | $1,739,056 |
|---|---|
| Salary | $308,928 |
| Total | $2,047,984 |
Dilly received $1.7M in option awards, accounting for 85% of the total pay in 2018.
Dilly also received $308.9K in salary.
Rankings
In 2018, Stephen G. Dilly's compensation ranked 5,607th out of 14,244 executives tracked by ExecPay. In other words, Dilly earned more than 60.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,607 out of 14,244 | 61st |
Division Manufacturing | 2,117 out of 5,765 | 63rd |
Major group Chemicals And Allied Products | 781 out of 2,128 | 63rd |
Industry group Drugs | 653 out of 1,817 | 64th |
Industry Pharmaceutical Preparations | 503 out of 1,391 | 64th |
Source: SEC filing on April 10, 2019.
Dilly's colleagues
We found five more compensation records of executives who worked with Stephen G. Dilly at Aimmune Therapeutics in 2018.
2018
Jayson Dallas
Aimmune Therapeutics
Chief Executive Officer
2018
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2018
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
2018
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
2018
Susan Barrowcliffe
Aimmune Therapeutics